Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 6262-year-old woman is evaluated in the hospital on postoperative day 6 following a total right knee arthroplasty. Since the surgery, she has been receiving prophylactic subcutaneous unfractionated heparin. Her postoperative course has been otherwise uncomplicated. Today, she reports new-onset swelling and dull pain in her right calf. Vital signs are temperature 37.2∘C37.2^\circ\text{C} (99.0∘F99.0^\circ\text{F}), blood pressure 128/82128/82 mmHg, pulse 8888/min, and respirations 1616/min. Physical examination reveals pitting edema and tenderness in the right lower extremity.

Laboratory TestResult
Platelet count95,000/mm395,000/\text{mm}^3
Preoperative platelet count260,000/mm3260,000/\text{mm}^3
Hemoglobin11.211.2 g/dL
Leukocyte count7,500/mm37,500/\text{mm}^3

A lower extremity venous duplex ultrasound is performed and confirms a new acute deep vein thrombosis in the right popliteal vein.

Which of the following is the most appropriate next step in the management of this patient?

  1. Discontinue unfractionated heparin and initiate argatrobanCevap
  2. B
    Continue unfractionated heparin and order a serotonin release assay
  3. C
    Continue unfractionated heparin and monitor platelet counts daily
  4. D
    Discontinue unfractionated heparin and initiate warfarin
  5. E
    Discontinue unfractionated heparin and initiate enoxaparin

Cevap

The most appropriate next step is to discontinue unfractionated heparin and initiate argatroban.
The correct action is to discontinue unfractionated heparin and initiate argatroban. This patient's presentation—a >50%>50\% decline in platelet count occurring 5 to 10 days after starting unfractionated heparin, coupled with a new venous thrombosis—is highly specific for heparin-induced thrombocytopenia (HIT) type 2. HIT is an immune-mediated disorder caused by IgG antibodies targeting complexes of heparin and platelet factor 4 (PF4). These antibodies activate platelets, creating a profoundly hypercoagulable state. The cornerstone of HIT management is the immediate cessation of all forms of heparin (including flushes) and the prompt initiation of a non-heparin anticoagulant. Direct thrombin inhibitors (e.g., argatroban, bivalirudin) or fondaparinux are the preferred agents.

Adım Adım Çözüm

1
Evaluate the timeline and laboratory changes in relation to the medication regimen.
The patient developed a greater than 50%50\% drop in her platelet count on postoperative day 6 after exposure to unfractionated heparin.
This specific timing and degree of thrombocytopenia are the classic hallmarks of heparin-induced thrombocytopenia (HIT) type 2.
2
Assess the new clinical findings alongside the laboratory data.
The patient has a newly confirmed deep vein thrombosis, classifying her condition as HIT with thrombosis (HITT).
HIT is a highly prothrombotic state. The formation of a new clot while on prophylactic heparin confirms therapeutic failure and immune-mediated platelet activation.
3
Determine the necessary treatment evaluation and modification.
All heparin products must be immediately discontinued, and an alternative, non-heparin anticoagulant (such as argatroban or fondaparinux) must be initiated.
Continued exposure to any form of heparin will fuel the immune response, leading to life-threatening thrombotic complications such as pulmonary embolism or limb gangrene.

Anahtar Kavram

Patients who develop a >50%>50\% drop in platelet count and new thrombosis within 5-10 days of heparin exposure have heparin-induced thrombocytopenia (HIT). Management requires immediately stopping all heparin products and initiating a non-heparin anticoagulant like argatroban or fondaparinux.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru